ACAD
30.46
-0.59
-1.90%
AEMD
0.25
0.00
-1.19%
APRI
1.39
-0.04
-2.80%
ARNA
4.32
-0.2
-4.32%
ATEC
1.29
-0.02
-1.53%
CFN
59.33
-0.28
-0.46%
CNAT
5.82
-0.14
-2.35%
CRXM
0.21
0.00
-1.38%
CYTX
0.48
+0.01
+1.89%
DXCM
59.81
-1.19
-1.95%
GNMK
12.89
-0.42
-3.16%
HALO
14.29
-0.3
-2.06%
ILMN
195.68
-4.32
-2.16%
INNV
0.22
+0.01
+4.19%
INO
8.33
-0.17
-2.00%
ISCO
0.06
0.00
0.00%
ISIS
68.56
-1.3
-1.86%
LGND
56.43
-0.6
-1.05%
LPTN
2.76
-0.09
-3.16%
MBVX
1.04
-0.01
-0.95%
MEIP
3.98
+0.12
+3.11%
MNOV
3.79
+0.02
+0.53%
MRTX
20.67
-0.62
-2.91%
MSTX
0.45
+0.01
+3.37%
NBIX
33.71
-0.64
-1.86%
NUVA
46.31
-0.99
-2.09%
ONCS
0.36
-0.01
-2.74%
ONVO
6.41
-0.28
-4.19%
OREX
5.26
-0.1
-1.78%
OTIC
29.25
-2.32
-7.35%
QDEL
23.53
-0.94
-3.84%
RCPT
110.06
-2.65
-2.35%
RGLS
19.15
+0.57
+3.04%
RMD
62.52
-0.51
-0.81%
SCIE
0.01
0.00
-2.65%
SPHS
0.48
+0.01
+1.34%
SRNE
10.1
-0.68
-6.31%
TROV
6.48
+0.65
+11.17%
VICL
1.03
-0.01
-0.96%
VOLC
17.96
0.00
0.00%
ZGNX
1.36
-0.01
-0.74%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

SynergEyes Announces New “Transform” Campaign

January 26, 2015 – 5:00 pm | Edit Post

CARLSBAD, Calif., Jan. 26, 2015 /PRNewswire/ –SynergEyes, Inc., the worldwide leader in hybrid contact lens technology, has announced a new marketing campaign: “Transform”. The campaign centers on SynergEyes contact lenses and how they can transform a…

Using 3D Printing, And Create Cartilage To Repair Tracheal Damage

January 26, 2015 – 5:00 pm | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Investigators at The Feinstein Institute for Medical Research have made a medical breakthrough using 3D printing on a MakerBot Replicator 2X Experimental 3D Printer to create cartilage designed for tracheal repair or replace…

Targeting protein could improve diagnosis and treatment of lymphoma

January 26, 2015 – 3:39 pm | Edit Post

Researchers develop new probe to measure MALT1 activity that may improve diagnostic and therapeutic tools for autoimmune disorders.

Aspyrian Therapeutics Raises $8.45 Million in Equity Financing

January 26, 2015 – 2:13 pm | Edit Post

Aspyrian Therapeutics Inc., a San Diego-based biotechnology startup, has raised $8.45 million in equity financing, according to a recent filing with the Securities and Exchange Commission.

3D Enzyme Model Provides New Tool for Anti-Inflammatory Drug Development

January 26, 2015 – 1:22 pm | Edit Post

To better understand PLA2 enzymes and help drive therapeutic drug development, researchers at University of California, San Diego School of Medicine developed 3D computer models that show exactly how two PLA2 enzymes extract their substrates from cellu…

SDSC Announces International Chemistry Collaboration

January 26, 2015 – 10:29 am | Edit Post
SDSC Announces International Chemistry Collaboration

The San Diego Supercomputer Center (SDSC) at the University of California, San Diego is a partner in a new international collaboration to develop computational models and software for simulations of bifunctional catalysis, which is of hi…

Network effect boosts S.D. biotech

January 26, 2015 – 10:04 am | Edit Post

San Diego biotech’s gravitational pull brings in companies and people from elsewhere.

Déjà Vu: UC San Diego Computer Scientist Passes the Test of Time Again

January 26, 2015 – 9:19 am | Edit Post
Déjà Vu: UC San Diego Computer Scientist Passes the Test of Time Again

For the second time in five years, CSE Prof. Victor Vianu is the recipient of the ACM PODS Alberto O. Mendelzon Test-of-Time Award. The annual award goes to the author or co-authors of a paper published in the proceedings of the Principl…

Innovation Outlook for 2015: Tackling Big Data Variety

January 26, 2015 – 9:16 am | Edit Post
Innovation Outlook for 2015: Tackling Big Data Variety

In 2015, look for the innovation community to be talking about Big Data Variety: the problem, how to fix it, how to make money off of it. Companies have invested roughly $3-4 trillion on enterprise…

[[Click headline to continue reading.]]

Trovagene’s Chief Scientific Officer to Present Precision Cancer Monitoring (SM) Platform Overview at the Personalized Medicine World Conference

January 26, 2015 – 6:35 am | Edit Post
Trovagene’s Chief Scientific Officer to Present Precision Cancer Monitoring (SM) Platform Overview at the Personalized Medicine World Conference

MOUNTAIN VIEW, Calif., Jan. 26, 2015 /PRNewswire/ — Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Chief Scientific Officer, Mark Erlander, Ph.D., will present an overview of the Company’s Precision Cancer MonitoringSM platform during the 2015 Personalized Medicine World Conference in Silicon Valley. Erlander’s presentation, titled “Quantitative Detection of Cancer Mutations in Liquid Biopsy Samples,” will be delivered today, during Track 1 at 11:15 a.m. PST.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine.  The Company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s Precision Cancer MonitoringSM platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.

Trovagene Contacts

Investor Relations

Media Relations

David Moskowitz and Amy Caterina

Investor Relations

Ian Stone

Account Director

Trovagene, Inc.

Canale Communications, Inc.

858-952-7593

619-849-5388

ir@trovagene.com

ian@canalecomm.com

Logo – http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

 

SOURCE Trovagene, Inc.